Teva Pharmaceutical Industries (TEVJF) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to 6.37%.
- Teva Pharmaceutical Industries' EBIT Margin rose 70500.0% to 6.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.49%, marking a year-over-year increase of 143200.0%. This contributed to the annual value of 12.5% for FY2025, which is 143300.0% up from last year.
- Per Teva Pharmaceutical Industries' latest filing, its EBIT Margin stood at 6.37% for Q4 2025, which was up 70500.0% from 19.69% recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' EBIT Margin registered a high of 19.69% during Q3 2025, and its lowest value of 25.54% during Q2 2022.
- Over the past 5 years, Teva Pharmaceutical Industries' median EBIT Margin value was 4.14% (recorded in 2021), while the average stood at 1.88%.
- Per our database at Business Quant, Teva Pharmaceutical Industries' EBIT Margin soared by 1251800bps in 2021 and then crashed by -404300bps in 2022.
- Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EBIT Margin stood at 1.9% in 2021, then tumbled by -1372bps to 24.2% in 2022, then skyrocketed by 170bps to 16.96% in 2023, then tumbled by -104bps to 0.69% in 2024, then skyrocketed by 1029bps to 6.37% in 2025.
- Its last three reported values are 6.37% in Q4 2025, 19.69% for Q3 2025, and 10.9% during Q2 2025.